<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872127</url>
  </required_header>
  <id_info>
    <org_study_id>MOSCASH</org_study_id>
    <nct_id>NCT04872127</nct_id>
  </id_info>
  <brief_title>Distal Versus Proximal Protection on Cerebral Microembolization During High-risk Carotid Artery Stenting</brief_title>
  <acronym>MOSCASH</acronym>
  <official_title>Distal Versus Proximal Protection on Cerebral Microembolization During High-risk Carotid Artery Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, outcome-assessor-blinded, randomized controlled trial study&#xD;
      (MOSCASH) is designed to compare the efficiency of distal and proximal embolism protection&#xD;
      devices during carotid angioplasty and stenting (CAS) procedure of patients with&#xD;
      high-intensity signal in the plaque on the time-of-flight magnetic resonance&#xD;
      angiography(TOF-MRA) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CAS is an alternative to carotid endarterectomy(CEA) for treating carotid stenosis with a&#xD;
      similar efficacy in preventing future stroke. High-intensity signal in the plaque on the&#xD;
      TOF-MRA is associated to a high risk of cerebral embolism during stenting. The evidence of&#xD;
      protection selection in such patients was limited. A multicenter, prospective,&#xD;
      outcome-assessor-blinded, randomized controlled trial study (MOSCASH) is designed to compare&#xD;
      the efficiency of distal and proximal embolism protection devices during CAS procedure of&#xD;
      patients with high-intensity signal in the plaque on the TOF-MRA. Asymptomatic patients with&#xD;
      internal carotid artery stenosis ≥ 70% (NASCET) and symptomatic patients with a stenosis ≥&#xD;
      50% who have a high-intensity signal in the relevant plaques on TOF-MRA will be included.&#xD;
      Patients are randomized in two balanced groups (1:1) to receive CAS with either distal&#xD;
      (Spider FX) or proximal (Mo.Ma Ultra) protection. The primary endpoint is the incidence of&#xD;
      new cerebral ipsilateral ischemic lesions on the Diffusion Weighted Imaging(DWI) in 7-days&#xD;
      post operation. Secondary endpoints include the number, size, location of new cerebral&#xD;
      ischemic lesions on the DWI, procedural complications, stroke, myocardial infarction, and&#xD;
      death in 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ipsilateral new ischemic lesions on DWI</measure>
    <time_frame>within 7 days post-operation</time_frame>
    <description>the incidence of ipsilateral new ischemic lesions on DWI after CAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major stroke</measure>
    <time_frame>within 7 days post-operation</time_frame>
    <description>the incidence of major stroke after CAS, defined as new onset of neurological symptoms causing an increase of NIHSS ≥ 4 or worsening of existing focal neurological deficit lasting ≥ 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>within 7 days post-operation</time_frame>
    <description>the incidence of myocardial infarction after CAS, defined as new onset of chest discomfort or cardiac stroke or heart failure with a rise and/or fall of cardiac biomarkers and ECG abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>within 7 days post-operation</time_frame>
    <description>In-hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other procedure-related complications</measure>
    <time_frame>within 7 days post-operation</time_frame>
    <description>including major/minor hemorrhage, acute kidney injury, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number, size, and location of new cerebral ischemic lesions on DW-MRI</measure>
    <time_frame>within 7 days post-operation</time_frame>
    <description>The number, size, and location of new cerebral ischemic lesions on DW-MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Stroke</condition>
  <condition>Carotid Stenosis</condition>
  <arm_group>
    <arm_group_label>CAS with proximal protection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using proximal embolism protection device during CAS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAS with distal protection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>using distal protection device during CAS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>proximal embolism protection device</intervention_name>
    <description>a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS</description>
    <arm_group_label>CAS with proximal protection</arm_group_label>
    <other_name>Mo.Ma Ultra (Invatec/Medtronic Vascular Inc, Santa Rosa, California)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>distal embolism protection device</intervention_name>
    <description>a distal SpiderFX will be used as the embolism protection device during CAS</description>
    <arm_group_label>CAS with distal protection</arm_group_label>
    <other_name>SpiderFX (Medtronic, Minneapolis, Minnesota, USA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients 40 years of age and older.&#xD;
&#xD;
          2. Asymptomatic patients with internal carotid artery stenosis≥70% on angiography.&#xD;
&#xD;
          3. Symptomatic patients with internal carotid artery stenosis≥50% on angiography.&#xD;
&#xD;
          4. High-intensity Signal in the relevant plaques on the TOF-MRA.&#xD;
&#xD;
          5. Anatomic characteristics of the lesions that made it possible to use either type of&#xD;
             embolism protective device (proximal or distal).&#xD;
&#xD;
          6. The patient or legally authorized representative has been informed of the nature of&#xD;
             the study, agrees to its provisions, and has provided written informed consent,&#xD;
             approved by the appropriate Medical Ethics Committee, Institutional Review Board, or&#xD;
             Human Research Ethics Committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Extensive ipsilateral or disabling stroke(mRS≥2).&#xD;
&#xD;
          2. Ischemic ipsilateral stroke in 15 days, with significant new ischemic lesions on the&#xD;
             DWI image.&#xD;
&#xD;
          3. Ipsilateral intracranial artery stenosis which needs to be treated at the same time.&#xD;
&#xD;
          4. Extremely calcified aortic arc that compromised the origin of the common carotid&#xD;
             artery or the brachiocephalic trunk.&#xD;
&#xD;
          5. Chronic or paroxysmal atrial fibrillation treated with oral anticoagulation.&#xD;
&#xD;
          6. Acute coronary syndrome in the 30-day period before the procedure.&#xD;
&#xD;
          7. Patient has a history of bleeding diathesis within 1 month or coagulopathy or patients&#xD;
             in whom antiplatelet and/or anticoagulant therapy is contraindicated.&#xD;
&#xD;
          8. Intolerance or allergic reaction to a study medication without a suitable management&#xD;
             alternative.&#xD;
&#xD;
          9. Pregnant or lactating female patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liqun Jiao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery &amp; Interventional Neuroradiology Xuanwu Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yabing Wang, MD</last_name>
    <phone>+8613911792272</phone>
    <email>wangyabing@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiding Feng, MD</last_name>
    <phone>+8615158071517</phone>
    <email>3100102434@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yabing Wang, MD</last_name>
      <phone>+8613911792272</phone>
      <email>wangyabing@foxmail.com</email>
    </contact>
    <investigator>
      <last_name>Liqun Jiao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yoshimura S, Yamada K, Kawasaki M, Asano T, Kanematsu M, Takamatsu M, Hara A, Iwama T. High-intensity signal on time-of-flight magnetic resonance angiography indicates carotid plaques at high risk for cerebral embolism during stenting. Stroke. 2011 Nov;42(11):3132-7. doi: 10.1161/STROKEAHA.111.615708. Epub 2011 Aug 25.</citation>
    <PMID>21868725</PMID>
  </reference>
  <reference>
    <citation>Cano MN, Kambara AM, de Cano SJ, Pezzi Portela LA, Paes ÂT, Costa JR Jr, Abizaid AA, Moreira SM, Sousa AG, Sousa JE. Randomized comparison of distal and proximal cerebral protection during carotid artery stenting. JACC Cardiovasc Interv. 2013 Nov;6(11):1203-9. doi: 10.1016/j.jcin.2013.07.006.</citation>
    <PMID>24262620</PMID>
  </reference>
  <reference>
    <citation>Akkaya E, Vuruskan E, Gul ZB, Yildirim A, Pusuroglu H, Surgit O, Kalkan AK, Akgul O, Akgul GP, Gul M. Cerebral microemboli and neurocognitive change after carotid artery stenting with different embolic protection devices. Int J Cardiol. 2014 Sep 20;176(2):478-83. doi: 10.1016/j.ijcard.2014.07.241. Epub 2014 Aug 12.</citation>
    <PMID>25125014</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carotid stenting</keyword>
  <keyword>embolism protection</keyword>
  <keyword>Carotid Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all individual participant data(IPD) that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>To share IPD in the magazine of paper published.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

